Ulcerative Colitis Study Gets Back On Track With Recruitment Support In Four Countries

A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis.
Study protocol originally accounted for randomizing 120 patients across 40 investigator sites in six EU countries. Full enrollment was expected after 14 months of campaigning.
However, after deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months.
This case study reviews how Trialbee partnered with the biotech to close the enrollment gap and move the study forward as planned.
VIEW THE CASE STUDY!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Hydrocarbon Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Trialbee AB
This website uses cookies to ensure you get the best experience on our website. Learn more